Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC

Next Previous
Trial Profile

A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Actinium 225 FL 020 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Acronyms ProTACT
  • Sponsors Full-Life Technologies

Most Recent Events

  • 29 Jan 2026 Planned number of patients changed from 35 to 50.
  • 29 Jan 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Jun 2026.
  • 29 Sep 2025 According to Full-Life Technologies media release,Full-Life Technologies announces US$77 Million Financing, this will support completion of global phase I trial of Actinium-225-FL-020*

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top